Rani Therapeutics to Release Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 29, 2022
Rani Therapeutics (Nasdaq: RANI) will announce its fourth quarter and full year 2021 financial results on March 29, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rani Therapeutics (Nasdaq: RANI) will announce its fourth quarter and full year 2021 financial results on March 29, 2022, after market close. A conference call to discuss these results will take place at 1:30 p.m. PT / 4:30 p.m. ET that same day. Rani Therapeutics focuses on the oral delivery of biologics, having developed the RaniPill™ capsule aimed at replacing subcutaneous injections. The company has conducted various preclinical and clinical studies to assess the safety and bioavailability of the RaniPill™ technology.
Positive
- Focused on advancing oral delivery of biologics, potentially reducing need for injections.
- Successfully conducted preclinical and clinical studies evaluating RaniPill™ capsule.
Negative
- None.
Details
News Market Reaction – RANI
The recorded move for RANI in the trading session of this news was +0.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company will release fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022 after the close of market. Rani will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business update.
Individuals interested in listening to the live conference call may do so by dialing (844) 605-7369 for domestic callers, or (929) 517-0917 for international callers and reference conference ID: 7192045; or from the webcast link in the investor relations section of the company's website at: www.ranitherapeutics.com.
A webcast replay will be available in the investor relations section on the company's website for 90 days following the completion of the call.
Rani Therapeutics
Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Rani has developed the RaniPill™ capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
Source: Rani Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.